Dr. Annalisa Jenkins Joins Biothera’s Board of Directors
EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today that noted pharmaceutical executive Dr. Annalisa Jenkins, MBBS, MRCP has joined its Board of Directors.
“Biothera’s immunotherapy that engages and directs the innate immune system against cancer has significant therapeutic potential”
Dr. Jenkins is the former Executive Vice President and Head of Global Research and Development at the biopharma division of Merck KGaA, Darmstadt, Germany. During her tenure at Merck, Dr. Jenkins was also responsible for Global Medical Affairs, Regulatory, Clinical Operations and Quality.
Previously, Dr. Jenkins held a number of senior positions during her 14-year career at Bristol-Myers Squibb, including Senior Vice President Global Medical. She was responsible for the company’s worldwide Medical Division that included 1,500 employees working across 46 medical departments in four regional teams.
“Dr. Jenkins’ experience in every aspect of pharmaceutical clinical development will be invaluable to future of Biothera and especially to the continued development of our cancer immunotherapy Imprime PGG®,” said Dan Conners, chairman of the board and president of the company’s Pharmaceutical Group.
“Biothera’s immunotherapy that engages and directs the innate immune system against cancer has significant therapeutic potential,” said Dr. Jenkins. “This is an exciting company with a tremendous opportunity to improve the lives of cancer patients.”
Dr. Jenkins began her career as a Medical Officer with the British Royal Navy, and served with the Minesweeper Squadron during the Gulf Conflict. A decorated officer, she achieved the rank of Surgeon Lieutenant Commander.
Dr. Jenkins graduated in Medicine from St. Bartholomew’s Hospital London and trained in Cardiovascular Medicine in the UK National Health Service.
About Imprime PGG®
Imprime PGG is a novel cancer immunotherapy that engages and directs the innate immune system to kill cancer cells. This targeted mechanism is synergistic with anti-tumor monoclonal antibodies, with significant therapeutic potential in a wide range of cancer indications. In phase 2 clinical trials, Imprime PGG has been associated with remarkable response rates in multiple clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer and chronic lymphocytic leukemia. Imprime PGG is currently being investigated in a phase 3 clinical trial for advanced colorectal cancer and in phase 2 studies for NSCLC, Non-Hodgkin lymphoma, and pancreas cancer. Website: www.biothera.com/pharma.
About Biothera, the Immune Health Company
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company is a pioneer in the field of cancer immunotherapy and the leader in innate immune modulation.